Treatment-emergent adverse events occurring in â‰¥5% of participants in any treatment group by preferred term Nausea 61 (25.8) 49 (20.6) 33 (13.6) 143 (19.9) 8 (1.1) Decreased appetite 40 (16.9) 28 (11.8) 20 (8.2) 88 (12.3) 1 (0.1) Vomiting 30 (12.7) 21 (8.8) 11 (4.5) 62 (8.6) 4 (0.6) Dyspepsia 27 (11.4) 27 (11.3) 15 (6.2) 69 (9.6) 4 (0.6) Diarrhea 26 (11.0) 36 (15.1) 29 (11.9) 91 (12.7) 17 (2.4) COVID-19 22 (9.3) 19 (8.0) 29 (11.9) 70 (9.8) 77 (10.9) Constipation 14 (5.9) 8 (3.4) 6 (2.5) 28 (3.9) 4 (0.6) Urinary tract infection 12 (5.1) 2 (0.8) 9 (3.7) 23 (3.2) 27 (3.8) All gastrointestinal adverse events 108 (45.8) 114 (47.9) 81 (33.3) 303 (42.3) 61 (8.6) Other treatment-emergent adverse events of interest Major adverse cardiovascular events (adjudication confirmed)d 3 (1.3) 7 (2.9) 5 (2.1) 15 (2.1) 12 (1.7) Hypersensitivity 6 (2.5) 7 (2.9) 4 (1.6) 17 (2.4) 9 (1.3) Cholelithiasis 4 (1.7) 3 (1.3) 2 (0.8) 9 (1.3) 2 (0.6) Injection-site reactions 4 (1.7) 3 (1.3) 1 (0.4) 8 (1.1) 1 (0.1) Acute cholecystitis 1 (0.4) 1 (0.4) 1 (0.4) 3 (0.4) 1 (0.1) Diabetic retinopathye 0 0 2 (0.8) 2 (0.3) 4 (0.6) Adjudication-confirmed pancreatitis 0 0000 a A serious adverse event was defined as any adverse event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, was a congenital anomaly or birth defect, or medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes previously listed.